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OBJECTIVES: Cost of illness (COI) studies can identify and measure all the costs of
a particular disease, including the direct, indirect and intangible dimension. They
provide estimates about the economic impact of costly disease. Alzheimer disease
(AD) is a relevant example to review cost of illness studies because of its costliness.
The aim of this study was to review relevant published cost studies of AD to ana-
lyze the method used and to identify which dimension had to be improve from a
methodological perspective. METHODS: We described the key points of cost study
methodology. Cost studies on AD were systematically reviewed. The methodolog-
ical choices of the studies that estimating AD costs were analyzed using an ana-
lytical grid which contains the main methodological items of COI studies.
RESULTS: Seventeen articles were retained. Depending on studies, annual total
cost of AD per patient varies from $2,935 to $52,954.Disease definition was made
mainly with NINCDS-ADRDA criterion and with MMSE for severity stage. The so-
cietal perspective was the mainly used perspective and both direct costs and in-
formal costs were assessed in 14 studies. A Prospective record was realized in 13
studies with a bottom-up approach. Resource consumption was mainly estimate
with questionnaires. Valuation of unit costs was mostly made with national esti-
mates, reimbursement tariffs and gross wage of a close substitute. Most studies
present results clearly and consistently set out in relation to the methods adopted.
Nevertheless, methods, data sources, and estimated cost categories in each study
varied widely. The review showed that cost studies adopted significantly different
approaches to estimate costs of AD, reflecting a lack of consensus on the method-
ology of cost studies. CONCLUSIONS: Commenting on these quantitative results is
problematic because of the different approaches adopted to assess AD costs. To
increase its credibility, closer agreement among researchers on the methodological
principles of cost studies would be desirable.
PND25
BURDEN OF SPINA BIFIDA (SB) IN GERMANY - THE CHARACTERISTICS OF SB
POPULATION
Schroeder A1, Joeckel M1, van Nooten F2, Lindemann M3, Lambrelli D4, Eriksson D4,
Raluy M4, Wasiak R4, Stein R1
1University of Medicine, Johannes Gutenberg University Mainz, Mainz, Germany, 2Astellas
Pharma Europe B.V., Leiderdorp, The Netherlands, 3Bayer Pharma AG, Berlin, Germany, 4United
BioSource Corporation, London, UK
OBJECTIVES: To assess characteristics of a population with SB, treated in a tertiary
reference center. METHODS: Participants were recruited from the tertiary clinic
database or when initiating care in the clinic. Participants had to have a verifiable
SB diagnosis, and a cognitive ability to respond to the questionnaire or a caregiver
able to answer questions. Data were double-entered with queries issued to patients
to improve data quality. Descriptive analyses were used to summarize data.
RESULTS: Of 88 participants, 49 were male (44%), 38 female (56%), mean (SD) age
was 28.713.5 years (range: 3-68 years). In 15 participants (17%) the lesion was
located in the sacral region/occult, in 55 lumbar (63%), and in 18 (20%) at thoracic/
cervical level. The majority had myelomeningocele (n62), 19 had meningocele, 2
had lipomenigocele and 5 had occult lesion; 59 (67%) had a hydrocephalus, 58 of
those were shunted. Of 88, 63% always used a wheelchair, 26% answered they used
it often, whereas 11% never used wheelchairs. 20 participants needed splints on
feet/legs, 10 were able to walk using a walking aid. Those with hydrocephalus
needed a wheelchair at younger age, compared to those without hydrocephalus
(5.7 vs. 15.3 years). Of 71 adults, more than 50% had BMI 25 (overweight), in 20%
BMI was 30 (obese). The most frequent comorbidities were abnormal bladder
function/incontinence (90.9%), paralysis (73.9%), hydrocephalus (67.1%), orthope-
dic problems (56.8%) and loss of ambulation (51.1%). Less than 50% reported Arnold
Chiari malformation (47.7%), gastrointestinal/bowel disorders (46.6%), skin integ-
rity/pressure sores (37.5%), latex allergic reaction (36.4%), and eye problems (31.8%).
Among all participants, 54 lived with their parents, 13 with a partner, and 11 alone.
CONCLUSIONS: Results indicate that SB may have substantial impact on general
health, with large number of comorbidities that require lifelong treatment. Such
treatment contributes to the overall burden associated with SB.
PND26
TREATMENT PATTERNS AND RESOURCE CONSUMPTION IN PATIENTS WITH
MULTIPLE SCLEROSIS (MS)-RELATED SPASTICITY IN GERMANY - RESULTS OF
MOVE 1 STUDY
Ehlken B1, Flachenecker P2, Zettl U3, Essner U4, Henze T5
1IMS Health, Munich, Germany, 2Neurological Centre for Rehabilitation - Quellenhof, Bad
Wildbad, Germany, 3University Hospital, Rostock, Germany, 4Almirall Hermal GmbH, Reinbek,
Germany, 5Centre for Rehabilitation, Nittenau, Germany
OBJECTIVES: To describe treatment patterns and resource consumption in pa-
tients with MS-related spasticity in Germany. METHODS: MOVE 1 (MObility Im-
proVEment) is a multi-centre, cross-sectional, retrospective burden-of-disease
study and combines a 12-month chart documentation with a patient questioning
at office-based neurologists, outpatients department at hospitals and rehabilita-
tion centers. Data were collected on demographical and clinical characteristics,
treatment patterns and resource consumption (e.g. drug treatment, physiotherapy,
OTC products). Direct costs were calculated from payer’s (statutory health insur-
ance) and patient’s perspective. RESULTS: In total, 419 patients were enrolled at 42
centers from 4-9/2011. 414 patients fulfilled selection criteria and were analyzed.
Mean age was 48.6 ( 9.6) years, 64.3% were female. According to physicians 27.3%
of patients had mild, 44.0% moderate and 28.7% severe spasticity. Onset of spas-
ticity was on average 8.2 ( 5.9) years before study inclusion. At study inclusion,
55.1% of patients had ongoing antispastic drug therapy (of these 55.3% received
baclofen). Percentages increased with increasing severity from 33.9% (mild) to
76.5% (severe). The majority of patients received drug mono-therapy (75.4%) or dual
therapy (20.2%). Overall, 37.7% of patients had used OTC products and dietary
supplements (of these 46.4% vitamins, 36.4% analgesics and 26.5% omega 3-fatty
acids). Within the last 12 months, 78.8% of patients had received physiotherapy
(mild: 66%; severe 86%). Mean costs per patient and year from payer perspective
amounted to €908 ( 991) for physiotherapy and €244 ( 467) for drugs. Stratified by
severity of spasticity, physiotherapy cost increases from €516 to €1351 and drug
cost from €85 to €458. Patients spent on average €14 ( 28) for drug co-payments,
€182 ( 208) for physiotherapy and €131 ( 319) for OTC products and dietary
supplements per year. CONCLUSIONS: This study provides first real-life data on
treatment patterns and resource consumption in patients with MS-related spas-
ticity in Germany.
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OBJECTIVES: To estimate economic value of informal care provided to patients in
situation of dependence with multiple sclerosis (MS). METHODS: Patients with MS
and their caregivers were identified through EDAD survey. The number of hours of
informal care provided was estimated. The method of cost replacement was used
to assess the economic value of this care. Two assessment scenarios were consid-
ered using “The Elderly in Spain” report (IMSERSO, 2008): the first one considered
the mean wage per hour of public service for home help of the 3 Autonomous
Regions of lower value, whereas the second scenario took into account the national
mean wage in order to estimate cost per hour. RESULTS: EDAD survey identified
368 patients with MS and some kind of disability. Average age was 64.26 years (SD:
16.82) and 73.91% were female. Average daily hours of care provided to people with
MS amounted to 10.27 (95% CI: 9.46 – 11.07). On an annual basis, average informal
care at home equalled 3,860 hours per MS patient. According to the assessment
scenarios considered, total mean costs of informal care at home ranged between
29,604 and 49,057 € per patient and year. When only the main informal carer at
home is considered, estimations yield 3,585 hours per MS patient and year,
whereas valuation ranged between 27,493 and 45,559 €. CONCLUSIONS: Informal
care of MS represents a high social burden. Dependence grade influences the need
to provide personal care. According to 2008 values, value of informal care provided
to people with MS is estimated at 29,604 – 49,057 € per patient and year.
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OBJECTIVES: Multiple sclerosis (MS) is one of the most frequent neurological dis-
eases and is associated with elevated health care costs. This study provides further
insights into these costs by differentiating between patients using different MS
drugs and by analysing different cost categories.METHODS: The database consists
of German claims data from 2006 to 2010. For the MS patients expenses of different
cost categories are analysed for each type of MS medication in the year 2009. These
categories cover costs for disease modifying drugs, symptomatic drug therapy,
primary care and hospitalization. RESULTS: In 2009, the mean annual costs per
patient amounted to roughly 15,000€ for disease modifying drugs and about 270€
for symptomatic drug therapy. Among the MS medications, Natalizumab caused
the highest treatment costs (25,104€), followed by Interferon beta-1a and Interferon
beta-1b with comparable costs (16,211€ and 16,519€) and Glatirameracetate
(12,617€). Azathioprine caused the lowest annual treatment costs (450€). The ex-
penditure for primary care (1,459€), hospital services (2,157€) and symptomatic
drug therapy (334€) is high for patients using Natalizumab, a drug which is indi-
cated for patients with highly active MS. Patients using Interferon beta-1a, Inter-
feron beta-1b and Glatirameracetate have similar expenses in those cost categories
(on average 872€ for primary care, 1409€ for hospital services and 212€ for symp-
tomatic drugs). Patients using Azathioprine have increased costs for symptomatic
drug therapy (316€) and hospital services (2,578€), while primary care expenditures
are comparable to patients using other basic MS therapy (770€). CONCLUSIONS:
The costs for specific MS medication makes up for 88% of the total annual drug
costs of MS patients. The expenses for other cost categories are similar for patients
treated with basic MS medication but higher for patients using escalating MS ther-
apy. Azathioprine is associated with lower medication costs but with slightly
higher expenses in the other observed cost categories.
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OBJECTIVES: To estimate the costs of multiple sclerosis according to severity of
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